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Background: The main objective of this study was to describe the inflammatory status of 
adolescents with Down Syndrome (DS) and their relationship with fatness. Methods: 95DS 
adolescents (44.2% girls) and a control group of 113 adolescents (47.8% girls), 11-18 years, 
from the UP&DOWN Study participated. Serum C-reactive protein (CRP), C3 and C4 
complement factors, total proteins, interleukin-6 (IL-6), tumor necrosis factor-α (TFN-α), 
insulin, cortisol, leptin, adiponectin, galactin-3 and visfatin were analyzed; HOMA-index was 
calculated. Body fat indicators: weight, height, waist circumference and skinfold thicknesses 
were measured. Birth weight was obtained by questionnaire. BMI, waist-to-height-ratio 
(WHtR) and body fat percentage (BF%) were calculated. Results: DS group showed higher 
levels of BMI, WHtR, waist circumference, BF%, and lower birth weight than controls 
(p<0.001). In the general lineal model in the total sample, WHtR was positively associated with 
C3 and C4 (p<0.001) as well as with leptin levels (p=0.015). BF% was positively associated 
with total proteins (p=0.093) and leptin levels (p<0.001). DS was positively associated with 
total proteins (p<0.001), C3 (p=0.047) and C4 (p=0.019). Despite the higher levels of fatness 
found in DS group, no direct association was found between BF% and leptin levels, opposite 
to the control group. Conclusions: these findings suggest that abdominal obesity should be 
controlled in adolescents due to its relationship with acute phase-inflammatory biomarkers, but 
especially on DS adolescents who may show a peculiar metabolic status according to their 
relationship between fatness and inflammatory biomarkers.
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Down Syndrome (DS) is a human genetic disorder due to the triplication of chromosome 21 
that is associated with several chronic pathologies, such as cardiovascular diseases, obesity, 
diabetes mellitus or Alzheimer (Roizen & Patterson 2003), together with a variety of 
dysmorphic physical characteristics, and immunodeficiency (Kusters et al. 2009). Autoimmune 
diseases occur more frequently in individuals with DS than in those without DS. However, the 
etiology of this immunological disorder has not been fully described (Santos-Silva CR, Biselli-
Périco JM et al. 2016).
Inflammation is a natural defense mechanism of body tissues from the immune system. 
Nevertheless, chronic inflammation is associated with the development of cardiovascular and 
metabolic diseases, such as atherosclerosis and type 2 diabetes. Fat tissue excess is related to a 
low-grade inflammation status that produces immune-related mediators, like adipokines that 
play an important role in sugar and fat metabolism, immunity and cardiovascular function 
(Smekal & Vaclavik 2017). 
Inflammatory conditions seem to have a crucial role in DS. However, this status of low-grade 
inflammation in DS has to be confirmed in humans (Fructuoso et al. 2018). Therefore, the main 
aim was to describe the inflammatory status of adolescents with Down Syndrome (DS) and 
their relationship with fatness.
Methods
Sample and study design
The UP & DOWN Study is a two-year follow-up study designed to assess the impact over time 
of physical activity and sedentary behaviors on health indicators, such as physical fitness, 
metabolic and cardiovascular disease risk factors, inflammatory biomarkers and mental health, 
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as well as to identify the psycho-environmental and genetic determinants of physical activity in 
a Spanish sample of adolescents with and without DS (Castro-Piñero et al. 2014). Parents and 
school supervisors were informed by letter about the nature and purpose of the study, and 
written informed consent was obtained. 
For the current study, we included initial data collected from September 2011 to June 2012 in 
Madrid (Spain), all the participants aged between 11 and 18 years with available blood samples 
were included.  The sample included a total of 95 DS adolescents (44.2% girls) (DS group) and 
113 adolescents (47.8% girls) (control group). The study protocols were approved by the Ethics 
Committee of Puerta de Hierro Hospital (Madrid, Spain) and the Bioethics Committee of the 
Spanish National Research Council (Madrid, Spain). The study conforms to recognized 
Declaration of Helsinki standards.
Inflammatory biomarkers
Fasting blood samples were collected early in the morning. In all cases, blood was extracted 
from the cubital vein according to the established protocol (Castro-Piñero et al. 2014). Twelve 
key biomarkers involved in the inflammatory process were analyzed for this study: C-reactive 
protein (CRP, mg/L), C3 (C3, mg/dL) and C4 component factors (C4, mg/dL) by turbidimetry 
(AU2700 Olympus Analyzer; Olympus UK Ltd, Watford, UK); total proteins (g/L) by 
colorimetric assay (AU2700 Olympus analyser); tumor necrosis factor-α (TNF-α pg/mL), 
interleukin-6 (IL-6, pg/mL), adiponectin (x106 pg/mL), insulin (pg/mL) and leptin (pg/mL) by 
Immunoassay (xMAP Techonology) using a kit (5 + 1) plex: 171B5006M Bio-Plex Human IL-
6 set; 171B5026M Bio-Plex Human TNF-α set; 171D50001 Bio-Plex Human Cytokine Stds; 
171-A7003M Bio-plex Pro Human Diabetes Adiponectin Assay; YB0000002Y Bio-Plex 
Human Diabetes 3-Plex Assay; visfatin (ng/mL) by Enzyme-linked ImmunoSorbent Assay 
(Human visfatin Elisa kit; Cusabio Biotech); galactin-3 (pg/mL) by enzyme-Linked 
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ImmunoSorbent Assay (Omnikine TM Human Galectin-3 Elisa Kit, Assay biotech) and cortisol 
(pg/mL) by enzyme-Linked ImmunoSorbent Assay (ARBOR ASSAYS kit). Also, homeostatic 
model assessment for insulin resistance (HOMA-IR) was calculated by the following equation: 
Fasting glucose (mmol/L)×fasting insulin (mIU/L)/22.5.
Fatness measurements
Body fat indicators were assessed following standardized procedures (Ruiz et al. 2011). Weight 
was measured using an electronic scale (model SECA 701, Hamburg, Germany) and height by 
using a telescopic height-measuring instrument (model SECA 220, Hamburg, Germany). Body 
mass index was expressed as kg/m2. As indices of abdominal obesity, both waist circumference 
[indicator of abdominal body fat, was measured with a non-elastic tape (SECA 200; SECA, 
Hamburg, Germany) at the level of the narrowest part of the torso] and waist-to-height ratio 
(WHtR) (indicator of abdominal body fat, was calculated as waist circumference/height) were 
used for this purpose. Body fat percentage (BF%) was calculated from triceps and subscapular 
skinfold thicknesses, that were measured with a Holtain caliper, using the Slaughter’s equations 
(Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, Van Loan MD 1988). 
These equations accurately predict body fat by these skinfolds in both populations (González-
Agüero et al. 2011; Rodríguez et al. 2005). Birth weight was obtained by a questionnaire. The 
whole protocol of the study had been previously described (Castro-Piñero et al. 2014).
Statistical analysis
Differences between groups (DS vs control) in age, birth weight, BMI, waist circumference, 
WHtR, BF%, C3 and C4 complements, CRP, total proteins, IL-6, TNF-α, insulin, HOMA-IR, 
cortisol, leptin, adiponectin, galactin-3 and cortisol were calculated using Student's t-test for 
independent samples (continuous variables).  Kolmogorov-Smirnov test was performed to 
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confirm the normal distribution of the variables. To normalize galactin-3 variable, natural 
logarithm was calculated. IL-6 and TNF-α did not present a normal distribution either with the 
calculation of box transformations.
Chi square test was analyzed to determine the differences between groups of visfatin detectable 
levels. In order to minimize the effect of multicollinearity for each biomarker, the most 
explicative covariates (age, gender, control or DS group, WHtR, BMI group, BF% and birth 
weight) were previously identified by a Stepwise Regression Analysis. Afterwards, a General 
Linear Model (GLM) was implemented to each biomarker from these fixed factors: DS, gender 
and BMI groups; and the following covariates: BF%, WHtR, birth weight and age. 
The analyses were performed using the Statistical Package for Social Sciences (SPSS, v. 24.0 
for WINDOWS; SPSS INC, Chicago) and the level of significance was set at p<0.05.
Results
Characteristics of the total sample are shown in Table 1. DS group showed higher levels of 
BMI, waist circumference, WHtR, and BF% while lower birth weight in comparison with the 
control group (p<0.001). Regarding inflammatory biomarkers, DS group showed higher levels 
of CRP, C3 and C4 complement factors, total proteins and visfatin while lower levels of 
adiponectin, insulin and galactin-3 than the control group (p<0.05). 
Visfatin levels were below the level of detection in 64.5% of the total sample, these levels were 
only detected in 44 (38.9%) adolescents from the control group and 23 (24.2%) DS adolescents 
(p=0.017).
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In the GLM, relationships between some body fat indicators and inflammatory biomarkers were 
found. WHtR was positively associated with C3 and C4 complement factors and leptin levels. 
The BF% was positively associated with leptin levels (Table 2). 
The feature to show this genetic disorder due to the triplication of chromosome 21 (DS group) 
seems to be related to higher levels of C3 and C4 complement factors and total proteins (Table 
2). In DS subjects no direct association was found between BF% and leptin levels, opposite to 
the results found in the control group (Figures 1 and 2).
Discussion 
This study provides original and useful information about the relationship between body fat 
indicators and metabolic and inflammatory status in healthy adolescents with DS through the 
evaluation of fatness and inflammatory biomarkers in this population. 
According to our knowledge, the scientific literature is scarce regarding the immune system in 
the population with DS. Some studies have assessed some immune biomarkers in a relatively 
low number of subjects (<43) with DS (Santos-Silva CR, Biselli-Périco JM et al. 2016; Corsi 
et al. 2009; SN et al. 2008) or in other studies showing conjunctly other diseases (Rohrer TR, 
Hennes P & Dost A, Grabert M, Rami B, Wiegand S 2010; Magni et al. 2004). On the other 
hand, the number of biomarkers analyzed in this study is much wider than in other studies. 
Nowadays, DS has been demonstrated to reveal an anthropometric dimorphism associated with 
their trisomy 21 (Real de Asua et al. 2014), what is clearly found in our results since practically 
all the body fat indicators determined, such as BMI, waist circumference, WHtR and BF%, 
showed higher values than the control group. These findings coincide with the results reported 
by other authors in both children and adolescents (Basil et al. 2016; Bertapelli et al. 2016), as 
well as in adults (Leti et al. 2015; Nespoli L, Burgio GR, Ugazio AG 1993). This outcome is in 
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agreement with the characteristics of DS subjects who suffer from overweight and obesity 
(Bertapelli et al. 2016), and also from abdominal obesity (Real de Asua et al. 2014).
Despite the evaluation of the immune system in DS population acquired certain interest few 
years ago (Nespoli L, Burgio GR, Ugazio AG 1993), in our opinion these studies lacked enough 
depth, especially when DS subjects are healthy and young. Therefore, our study aimed to 
evaluate the inflammatory status of this population with a battery of inflammatory biomarkers 
of acute phase, such as CRP, C3, C4 and total proteins. All these markers showed higher levels 
in the DS group than in the control group. Other studies have found similar results related to 
C3 and C4 complement factors, but in adult population with DS and with other pathologies 
(Nanjo et al. 2014). However, to our knowledge there are not studies on healthy youth with DS. 
All these molecules analyzed in our study are considered early cardiovascular risk markers, 
whose high values are indicative of low-grade inflammation, especially in adolescents with 
overweight and obesity. We have found a positive relationship between abdominal obesity 
(assessed by WHtR) and C3 and C4 complement factors (Table 2) in the total adolescents, both 
with and without DS, that means both biomarkers are related to body fat distribution, in 
agreement with previous results evaluating the excess of abdominal fat in children and 
adolescents without DS (Warnberg et al. 2018). On the other hand, the DS group showed higher 
levels of total proteins than controls (Tables 1,2). Total protein values include serum albumin 
and globulins that were also assessed since DS subjects are more prone to suffer from infectious 
diseases (Santos-Silva CR, Biselli-Périco JM et al. 2016). According to Mahan et al. (Mahan 
LK, Escott-Stump, S 2013) this result could be related to an increase of globulins revealing an 
immune response triggered by an infectious agent. On the other hand, an association between 
total proteins and lean body mass has also been observed in adults with renal treatment (Gallar-
Ruiz et al. 2012). Nevertheless, we must highlight that no infections were detected in the DS 
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group assessed in the current study, therefore, the evaluation of all markers, as a whole, is 
necessary to understand the real inflammation status of this population.   
Due to the higher levels of body fat showed by adolescents with DS, we included the assessment 
of some molecules such as insulin and HOMA-IR, cortisol, leptin, adiponectin, galactin-3 and 
visfatin in order to evaluate their impact at the metabolic level. In addition, it is important to 
highlight that DS subjects show an increased risk of both type 1 (Rohrer TR, Hennes P & Dost 
A, Grabert M, Rami B, Wiegand S 2010) and type 2 diabetes (Helguera et al. 2013). 
Adolescents with DS showed lower insulin concentration and a trend towards lower HOMA-
IR values in comparison with controls (Table 1), according to other studies performed in 
children and adolescents (Bertapelli et al. 2016) or adults (Leti et al. 2015) with DS and also in 
validated DS mice models (Peiris et al. 2016). According to Rohrer et al. (Rohrer TR, Hennes 
P & Dost A, Grabert M, Rami B, Wiegand S 2010), youth with DS use less insulin since they 
seem to have a better metabolism control. On the other hand, HOMA-IR remained unmodified 
between both groups (Table 1), in agreement with other authors (SN et al. 2008). However, a 
relationship between obesity and hyperinsulinemia has been found in children with DS (Basil 
et al. 2016), although there is not a consistent association.
Cortisol is well-known to be a steroid hormone that is produced in the hypothalamic-pituitary-
adrenal axis and has been positively associated with adipose tissue and low-grade inflammation, 
especially in obese subjects (Smekal & Vaclavik 2017).  However, in our sample cortisol levels 
remained similar in both groups (DS and control) even though DS adolescents showed higher 
BMI and BF% than the control group. This result is not in accordance with that found in another 
study (Bricout et al. 2008) reporting lower levels of cortisol in young adults (22.5 years old) 
with DS in comparison with a control group. In addition, since cortisol levels raise with age in 
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the adult general population (Pal & Singh 2014), we could elucubrate that this result could be 
due to the different age range in both studies.
Leptin is another adipokine assessed in the current study as a hormone involved in food and 
appetite regulations. Leptin levels remained unmodified between both groups in the current 
study (Table 1), opposite result to that found in youth (Corsi et al. 2009; SN et al. 2008) and 
adults (Leti et al. 2015) with DS, despite leptin has been associated with high BMI in prepuberal 
youth with DS (Magni et al. 2004). Indeed, this result coincides with our findings in the general 
lineal model, where trisomy 21 did not present the same direct relationship between body 
composition and WHtR and leptin levels in comparison with the control group (Table 2, Figures 
1 y 2). May be, this is the reason why other studies have accepted a lack in the knowledge of 
the relationship between adiposity and inflammation in DS subjects (Fructuoso et al. 2018).
Adiponectin is a hormone involved in glucose regulation and fatty acid catabolism, with 
cardioprotective characteristics and probably with an anti-inflammatory effect (Shetty et al. 
2009). In the current study, DS adolescents showed lower adiponectin levels than the control 
group (Table 1). These results are in agreement with Martínez-Gómez et al. (Martinez-Gomez 
et al. 2012) and Turer et al. (Turer et al. 2011) studies in healthy adolescents and adults, 
respectively, and in a smaller sample of children with DS (Tenneti et al. 2017). However, such 
inflammatory risk seems to be diminished with aging, decreasing also the cardiovascular risk 
(Corsi et al. 2009). Maybe this fact could contribute to a lower prevalence of cardiovascular 
mortality in the DS population (Uppal et al. 2015). 
The high percentage of congenital coronary alterations found in the DS population (Diogenes 
et al. 2017) acquires a great interest, despite not being the main cause of mortality (Uppal et al. 
2015). Therefore, we included the assessment of galactin-3 as a marker of cardiovascular 
pathologies (de Boer et al. 2012; De Boer et al. 2014; Vassalle et al. 2017). In the current study, 
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adolescents with DS showed lower levels of galactin-3 than the control group (Table 1). 
However, opposite results in Ts65Dn have been found in adult mice, a validated trisomy 21 
model (Fructuoso et al. 2018). These controversial results could be due to the different age-
range in these studies since galactin-3 increases with age in general population (de Boer et al. 
2012). 
Visfatin is secreted by visceral fat (Smekal & Vaclavik 2017), being usually increased in 
cardiovascular diseases (Turer et al. 2012), and related to insulin resistance and type 2 diabetes 
(Chen et al. 2006) in general population. DS subjects showed higher visfatin values than the 
control group (Table 1). In the same way, several authors have pointed out a positive association 
between visfatin and BMI as well as WHtR index in DS adolescents (Blüher et al. 2017); and 
also with BF% in children (García-Hermoso et al. 2017) and adults (Turer et al. 2012) without 
DS. It is highlighted that despite most DS subjects had undetectable levels of visfatin, when 
these levels were detectable, they were higher in DS subjects than in the control group (Table 
1). 
Finally, our findings demonstrate that adolescents with DS show higher body fat indicators, 
which lead to a higher risk of obesity. Furthermore, abdominal obesity, through WHtR 
assessment, is positively related to inflammatory and cardiovascular risk biomarkers such as 
C3 and C4 complement factors and leptin. Therefore, in agreement with other authors, this 
anthropometric index should be taken into account in children and adolescents, being especially 
important in DS population where exist other idiosyncratic factors such as trisomy 21 that may 
get worse an inflammatory status. However, in view of these results we could interpret that this 
chromosomic alteration may be a metabolic modulator effect on variables such as leptin. Thus, 
it seems that adolescents with DS may show a peculiar inflammatory and metabolic behavior, 
different from control subjects at the same age. 
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The principal limitation of the current study is the cross-sectional design, which does not allow 
us to read any conclusion about the causal direction of associations. Likewise, the sample could 
not be adjusted by pubertal development due to complications found in the self-reported data 
collection in the DS group. However, as strength, the relative large sample of adolescents with 
DS and the large number of biomarkers analyzed should be highlighted, in the context of few 
previous studies assessing the interactions between inflammatory biomarkers and body fat 
indicators in adolescents with DS.
Indeed, the knowledge of the relationship between body fat indicators and inflammatory 
biomarkers in DS could be a big help in the control of associated pathologies to the DS 
chromosomic alteration. In future investigations, the assessment of molecules such as C3 and 
C4 complement factors, total proteins, visfatin and leptin could be helpful to understand their 
different behavior in youth with DS. In addition, interventions in subjects with DS addressed 
to enhance their body composition must be performed in order to avoid any inflammation status 
risk, especially nowadays when their life expectancy is increasing.    
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Table 1. Description of main variables in both groups, Down Syndrome and control 
groups
Control Down Syndrome
n Mean (SD)a n Mean (SD) p-value
Age (years) 113 14.64 (2.16) 95 14.22 (2.00) 0.172
Birth weight (kg) 108 3.16 (0.64) 67 2.77 (0.81) <0.001




113 62.21 (7.88) 95 74.03 (9.72) <0.001
WHtRc (cm/cm) 112 0.41 (0.03) 95 0.49 (0.06) <0.001
BFd % 113 18.91 (6.12) 91 29.26 (5.44) <0.001
CRPe (mg/L) 57 0.90 (2.68) 87 4.49 (9.31) 0.001
C3 (mg/dL) 105 91.90 (24.65) 90 119.75 (22.52) <0.001
C4 (mg/dL) 105 20.11 (9.30) 90 30.06 (9.09) <0.001
Total proteins 
(g/L) 77 58.74 (15.68) 90 72.21 (5.37) <0.001
IL-6f (pg/mL) 112 28.18 (25.07) 87 37.75 (46.31) 0.086
TNF-αg (pg/mL) 100 78.04 (76.40) 68 71.75 (112.4) 0.666
Insulin (pg/mL) 81 413.5 (368.4) 56 243.9 (347.6) 0.008
HOMA-IRh 
(mmol/L*mIU/L) 78 2.34 (2.24) 53 1.57 (2.28) 0.061
Cortisol (pg/mL) 102 197972 (102877) 87
173669 
(86454) 0.083











Visfatin (ng/mL) 44 0.93 (0.78) 23 1.40 (0.75) 0.019
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a Standard deviation; b Body mass index; c Waist to height ratio; d Body fat; e C-reactive protein; 
f Interleukin-6; g Tumor necrosis factor-α; h Homeostatic model assessment for insulin 
resistance (HOMA-IR).  
*Statistical significance was determined by Student's t-test.
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Table 2. Analysis of inflammatory biomarkers in adolescents with and without Down 











Squared=0.347 WHtRc 195.094 36.940 <0.001




Squared=0.280 WHtRc 58.070 14.773 <0.001




Squared=0.264 BFd % 0.261 0.155 0.093
Control 7286.864 1872.830 <0.001
DSb 0a




WHtRc 35660.685 14543.828 0.015
a Down Syndrome; b This parameter is set to zero becaus  it is redundant; c Waist to height 
ratio; d Body fat. 
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Title: Relationship between leptin levels and body fat percentage in youth with and without 
Down Syndrome
Figure 2
Title: Relationship between leptin levels and WHtR in youth with and without Down Syndrome
Foot of figure: WHtR, Waist to height ratio
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